Current Editions
It is past time for biopharma CEOs to speak out and affirm basic truths, even if it puts them in harm’s way
Editor's Commentary
Product Development
New name, plans to domicile in Switzerland reflect maturation of oncology player
Emerging Company Profile
Latest spinout from David Baker’s IPD rescuing failed mAbs by forcing them into cage-like structures for better biodistribution, target engagement
Deals
Marketer of Keytruda takes rights to bifunctional molecule in class that could compete directly with its top seller
On the eve of Jefferies London conference, a view on what the new U.K., U.S. governments, with improving financial markets, mean for M&A and private equity
Management Tracks
Plus: Veronica Fonck becomes chair of MinervaX, and updates from Grey Wolf, Actimed and Caszyme
BioCentury ISSN 1097-7201